Cardax Inc Revenue Growth Rates (CDXI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Cardax Inc   (CDXI)
 

CDXI's Revenue Growth by Quarter and Year

Cardax Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CDXI Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 0.10
FY 0.10

CDXIs Annual Revenue
Cardax Inc 's Revenue in the fiscal year 2020 $ 0.54 millions
Cardax Inc 's Revenue in the fiscal year 2019 $ 0.71 millions
Cardax Inc 's Revenue in the fiscal year 2018 $ 1.51 millions
Cardax Inc 's Revenue in the fiscal year 2017 $ 0.61 millions
Cardax Inc 's Revenue in the fiscal year 2016 $ 0.04 millions




CDXI Revenue first quarter 2021 Y/Y Growth Comment
Cardax Inc reported fall in Revenue in the first quarter 2021 by -25.3% to $ 0.10 millions, from the same quarter in 2020.
The drop in the first quarter 2021 Cardax Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 231.19%.

Looking into first quarter 2021 results within Major Pharmaceutical Preparations industry 88 other companies have achieved higher Revenue growth. While Cardax Inc ' s Revenue drop of -25.3% ranks overall at the positon no. 3416 in the first quarter 2021.


CDXI Revenue ( Y/Y Growth %) 2021
 2020 2019 2018
4th Quarter December - -25.93 % -28.95 % 245.45 %
3rd Quarter September - -69.57 % -58.18 % 71.88 %
2nd Quarter June - 160 % -81.48 % 285.71 %
1st Quarter March -25.3 % -12.5 % -48.39 % 181.82 %
FY   - -23.94 % -52.98 % -

Financial Statements
Cardax Inc 's first quarter 2021 Revenue $ 0.10 millions CDXI's Income Statement
Cardax Inc 's first quarter 2020 Revenue $ 0.14 millions Quarterly CDXI's Income Statement


CDXI Revenue (Quarter on Quarter Growth %)

 2021
 2020 2019 2018
4th Quarter December - 185.71 % 17.39 % -30.91 %
3rd Quarter September - -46.15 % 360 % 103.7 %
2nd Quarter June - -7.14 % -68.75 % -12.9 %
1st Quarter March -47.71 % -48.15 % -57.89 % 181.82 %
FY (Year on Year)   - -23.94 % -52.98 % -


Back to CDXI Growth rate Comparisons >> Back to CDXI Growth rate Comparisons >>


Revenue first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #89
Healthcare Sector #495
Overall #3416

Revenue Y/Y Growth Statistics
High Average Low
2784.06 % 231.19 % -100 %
(Sep 30 2017)   (Dec 31 2014)
Revenue first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #89
Healthcare Sector #495
Overall #3416
Revenue Y/Y Growth Statistics
High Average Low
2784.06 % 231.19 % -100 %
(Sep 30 2017)   (Dec 31 2014)

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Cardax Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
404.82 % 64.01 % -100 %
(Sep 30 2019)  


CDXI's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2021 Cardax Inc disclosed fall in Revenue from the fourth quarter by -47.71% to $ 0.10 millions, from $ 0.20 millions achived in the previous reporting period.

But that's not important problem, as Cardax Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 205 other companies have achieved higher Revenue quarter on quarter growth. While Cardax Inc 's Revenue growth quarter on quarter, overall rank is 3443.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #206
Healthcare Sector #501
Overall #3443
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #206
Healthcare Sector #501
Overall #3443
Revenue Q/Q Growth Statistics
High Average Low
404.82 % 64.01 % -100 %
(Sep 30 2019)  


CDXI's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2021 Cardax Inc disclosed fall in Revenue from the fourth quarter by -47.71% to $ 0.10 millions, from $ 0.20 millions achived in the previous reporting period.

But that's not important problem, as Cardax Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 205 other companies have achieved higher Revenue quarter on quarter growth. While Cardax Inc 's Revenue growth quarter on quarter, overall rank is 3443.


Cardax Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2021)		 12 Months Ending
(Dec 31 2020)		 12 Months Ending
(Sep 30 2020)		 12 Months Ending
(Jun 30 2020)		 12 Months Ending
(Mar 31 2020)
Cumulative Revenue 12 Months Ending $ 0.50 $ 0.54 $ 0.62 $ 0.78 $ 0.69
Y / Y Revenue Growth (TTM) -27.31 % -24.19 % -24.55 % -31.51 % -49.45 %
Year on Year Revenue Growth Overall Ranking # 3417 # 2997 # 2998 # 2822 # 284
Seqeuential Revenue Change (TTM) -7.1 % -12.41 % -20.91 % 12.94 % -3.12 %
Seq. Revenue Growth (TTM) Overall Ranking # 2238 # 3301 # 3684 # 217 # 2600


Cumulative Revenue growth Comment
Cardax Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -27.31% year on year, at Mar 31 2021 compare to the -24.19% decrease at Dec 31 2020. If the Cardax Inc 's fiscal year would end at Mar 31 2021, annual Revenue would be $1 millions.

In the Healthcare sector 477 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2997 to 3417.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 138
Healthcare Sector # 478
Overall # 3417

Revenue TTM Y/Y Growth Statistics
High Average Low
387.6 %
 42.41 %
-52.94 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 138
Sector # 332
S&P 500 # 2238
Cumulative Revenue growth Comment
Cardax Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -27.31% year on year, at Mar 31 2021 compare to the -24.19% decrease at Dec 31 2020. If the Cardax Inc 's fiscal year would end at Mar 31 2021, annual Revenue would be $1 millions.

In the Healthcare sector 477 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2997 to 3417.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 138
Healthcare Sector # 478
Overall # 3417

Revenue TTM Y/Y Growth Statistics
High Average Low
387.6 %
42.41 %
-52.94 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 138
Sector # 332
S&P 500 # 2238




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CDXI's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Mar 31 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2021
Neurocrine Biosciences Inc -0.21%$ -0.211 millions
U S Physical Therapy Inc-0.31%$ -0.310 millions
Community Health Systems Inc -0.40%$ -0.397 millions
Davita Inc -0.75%$ -0.747 millions
Travere Therapeutics Inc -0.76%$ -0.758 millions
Neurometrix Inc -0.76%$ -0.763 millions
Amneal Pharmaceuticals Inc -0.80%$ -0.799 millions
Escalon Medical Corp -1.38%$ -1.378 millions
Allied Healthcare Products inc -1.61%$ -1.607 millions
Inogen Inc -1.76%$ -1.760 millions
Carlisle Companies Incorporated-1.91%$ -1.908 millions
National Healthcare Corp-2.01%$ -2.011 millions
Tactile Systems Technology Inc -2.07%$ -2.068 millions
Eyepoint Inc -2.22%$ -2.217 millions
Rockwell Medical inc -2.42%$ -2.419 millions
Old Ayala Inc -2.70%$ -2.697 millions
Inspiremd Inc -2.71%$ -2.708 millions
Mimedx Group Inc -2.87%$ -2.865 millions
Bioadaptives Inc -2.94%$ -2.943 millions
Anika Therapeutics Inc -3.12%$ -3.122 millions
Biomarin Pharmaceutical Inc-3.19%$ -3.195 millions
Icu Medical Inc-3.21%$ -3.214 millions
Horizon Therapeutics Public Limited Company-3.79%$ -3.794 millions
Amgen Inc -4.22%$ -4.220 millions
Fuse Medical Inc -4.22%$ -4.222 millions
Vaso Corporation-4.42%$ -4.421 millions
Stablecoin Development Corporation-4.49%$ -4.493 millions
Cidara Therapeutics Inc -4.82%$ -4.822 millions
Guardion Health Sciences Inc -5.06%$ -5.057 millions
Prestige Consumer Healthcare Inc -5.36%$ -5.363 millions


About Cardax Inc Revenue Growth Rates (CDXI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.